Dronedarone for AF rejected in draft NICE guidance

Dronedarone is not cost effective for AF treatment and cannot be recommended for use in the NHS, draft NICE guidance has concluded.

NICE research found that dronedarone cost more and was less effective
NICE research found that dronedarone cost more and was less effective

NICE said in a statement that the evidence it had reviewed in formulating the draft guidance suggested that dronedarone (Multaq) was less effective and cost ‘considerably more' than existing treatments for controlling AF.

NICE's chief executive Andrew Dillon said the institute was keen to help AF patients. ‘But,' he said, ‘we need to be sure that any treatment we recommend offers real additional benefits for patients — and we need to be confident that those benefits justify the cost to the NHS. In this case, dronedarone costs more, and has not been shown to be more effective, than other treatments for AF.'

Multaq's manufacturer Sanofi-aventis said it was disappointed at the decision.

'Multaq represents one of the most important pharmacological innovations in the treatment of AF for 20 years as it is the only anti-arrhythmic drug which, beyond prolonging time to AF recurrence and providing rate control, is proven to reduce the composite end-point of CV hospitalisation and death in AF patients, all achieved with a favourable safety profile,' the company said in a statement. 'No currently available anti-arrhythmic drugs have ever proven a clinical benefit in reducing outcomes in AF. Multaq represents a significant therapeutic advance in this regard.'

Sanofi-aventis said it would continue to work to ensure that Multaq is made available to those patients who will benefit from this new AF treatment.

NICE's draft recommendations is open to consultation until 28 January.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

MHRA approves Pfizer/BioNTech jab paving way for COVID-19 vaccination to start

MHRA approves Pfizer/BioNTech jab paving way for COVID-19 vaccination to start

The MHRA has approved the Pfizer/BioNTech COVID-19 vaccine for use in the UK and...

Enhanced service contract for GP practices delivering COVID-19 vaccine revealed

Enhanced service contract for GP practices delivering COVID-19 vaccine revealed

GP practices have until midnight on 7 December to sign up to a COVID-19 enhanced...

Five GP practices a week inspected by CQC during pandemic second wave

Five GP practices a week inspected by CQC during pandemic second wave

The CQC has inspected five GP practices a week in England since the second wave of...

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women, children and under-18s will not be recommended for routine COVID-19...

GP training: How an audit e-portfolio log entry is assessed

GP training: How an audit e-portfolio log entry is assessed

The second of two articles on audit during GP training looks at how the quality improvement...

GP training: Writing up an audit for your e-portfolio

GP training: Writing up an audit for your e-portfolio

In the first of two articles on how to write up an audit, a typical e-portfolio entry...